EULAR Impact of Rheumatic and Musculoskeletal Diseases Survey

Musculoskeletal Diseases Clinical Trial

— ImpactSurvey  

Official title:

EULAR Impact of Rheumatic and Musculoskeletal Diseases Survey

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06461000
• Other study ID #: EPI001
• Status: Not yet recruiting
• Start date: June 12, 2024
• Est. completion date: June 12, 2029

Study information

• Verified date: June 2024
• Source: European Alliance of Associations in Rheumatology
• Contact: Coralie Signorell, PhD
• Phone: 0445751564
• Email: coralie.signorell[@]eular.org
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The EULAR Impact of RMDs Survey collects first-hand information about the impact of rheumatic and musculoskeletal diseases (RMDs) among patients across and beyond Europe. Through periodic questionnaires, patients will provide information about their healthcare situation, and how the disease affects their social and occupational lives. This data will be an important resource for researchers, healthcare professionals, and patients alike, providing valuable insights into the burden of disease and helping improve the overall care for people living with these conditions.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1000
• Est. completion date: June 12, 2029
• Est. primary completion date: June 12, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18-year-old at time of baseline survey
• Living in a EULAR country at time of baseline survey
• Diagnosed with at least one RMD
• Valid personal e-mail address
• Being able to use an internet website

Exclusion Criteria:

• none

Related Conditions & MeSH terms

• Collagen Diseases
• Musculoskeletal Diseases
• Rheumatic Diseases
• Rheumatologic Disease

Intervention

Other:
• Survey
online survey for participants

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
European Alliance of Associations in Rheumatology

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	General population description - country	country of residence	every 6 months for up to 5 years
Primary	General population description - diagnosis	diagnosis (name of the disease)	every 6 months for up to 5 years
Primary	General population description	year of birth	every 6 months for up to 5 years
Secondary	Diagnosis history - physician treating the RMD	Primary physician specialty treating the patient	every 6 months for up to 5 years
Secondary	Diagnosis history - outpatient care history	number of medical appointments for the past 6 months	every 6 months for up to 5 years
Secondary	Diagnosis history - timeline	waiting time for medical appointments and time spent in medical appointments	every 6 months for up to 5 years
Secondary	Diagnosis history - Inpatient care	number of days of hospitalization during the past 6 months.	every 6 months for up to 5 years
Secondary	Non-pharmacological and pharmacological treatments.	Names of medications taken by the patients (from a list)	every 6 months for up to 5 years
Secondary	Other chronic diseases	diagnosis of chronic diseases other than RMD and medication taken for these conditions.	every 6 months for up to 5 years
Secondary	Disease burden - impact of disease	Rheumatic Arthritis Impact of Disease (RAID) version 7 questionnaire	every 6 months for up to 5 years
Secondary	Disease burden - health assessment	Health assessment questionnaire version 2 (HAQ2)	every 6 months for up to 5 years
Secondary	Disease burden - quality of life	patient health questionnaire (PHQ-8)	every 6 months for up to 5 years
Secondary	Consequences on work and life	work productivity and activity impairment questionnaire (WPAI), including total number of sick leave days due to RMD in the past 6 months.	every 6 months for up to 5 years
Secondary	Other barriers due to RMD	impact on family, leisure, social and work activities (quality of life questionnaire)	every 6 months for up to 5 years
Secondary	Health care	support from professionals (general questionnaire), satisfaction with care (scale, 1= low, 5 = high satisfaction)	every 6 months for up to 5 years
Secondary	Demographics - persons living with patient	number of persons living in household	every 6 months for up to 5 years
Secondary	Demographics - professional status	professional status	every 6 months for up to 5 years

External Links

•   EULAR Impact of RMDs Survey